Abeona Therapeutics (NASDAQ: ABEO) shares are trading higher on Friday after B. Riley FBR initiated coverage on the stock with a Buy rating and announced a price target of $5 per share.
Abeona Therapeutics is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease.
The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-50X for the treatment of retinal diseases.
Abeona Therapeutics shares were up 14.80% at $2.25 at the time of publication on Friday. The stock has a 52-week high of $5.19 and a 52-week low of $1.35.
Latest Ratings for ABEO
View More Analyst Ratings for ABEO View the Latest Analyst Ratings
See more from Benzinga
2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Go here to read the rest:
Why Abeona Therapeutics Is Trading Higher Today - Yahoo Finance
Recommendation and review posted by G. Smith
